TY - JOUR
T1 - Pemetrexed for Treatment of Advanced Non-Small Cell Lung Cancer
AU - Fossella, Frank V.
PY - 2004/2
Y1 - 2004/2
N2 - The novel antifolate pemetrexed targets multiple enzymes involved in folate metabolism, resulting in inhibition of DNA synthesis. Pemetrexed has shown antitumor activity in preclinical models against a variety of tumor types, including non-small cell lung cancer. Phase II studies have confirmed its single-agent activity and manageable toxicity profile, and pemetrexed has shown antitumor activity in combination with other chemotherapeutics, including gemcitabine, taxanes, platinums, and vinorelbine, in the first-line treatment of advanced non-small cell lung cancer. A large ongoing phase III trial is comparing the activity of pemetrexed versus docetaxel in the second-line setting. Supplementation with oral folic acid and vitamin B12 was shown to reduce pemetrexed-related toxicity and increase its therapeutic index. These data suggest that pemetrexed has significant activity in advanced non-small cell lung cancer and represents a new treatment option for patients with this disease.
AB - The novel antifolate pemetrexed targets multiple enzymes involved in folate metabolism, resulting in inhibition of DNA synthesis. Pemetrexed has shown antitumor activity in preclinical models against a variety of tumor types, including non-small cell lung cancer. Phase II studies have confirmed its single-agent activity and manageable toxicity profile, and pemetrexed has shown antitumor activity in combination with other chemotherapeutics, including gemcitabine, taxanes, platinums, and vinorelbine, in the first-line treatment of advanced non-small cell lung cancer. A large ongoing phase III trial is comparing the activity of pemetrexed versus docetaxel in the second-line setting. Supplementation with oral folic acid and vitamin B12 was shown to reduce pemetrexed-related toxicity and increase its therapeutic index. These data suggest that pemetrexed has significant activity in advanced non-small cell lung cancer and represents a new treatment option for patients with this disease.
UR - http://www.scopus.com/inward/record.url?scp=1242318818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1242318818&partnerID=8YFLogxK
U2 - 10.1053/j.seminoncol.2003.12.001
DO - 10.1053/j.seminoncol.2003.12.001
M3 - Article
C2 - 14981587
AN - SCOPUS:1242318818
SN - 0093-7754
VL - 31
SP - 100
EP - 105
JO - Seminars in oncology
JF - Seminars in oncology
IS - 1 SUPPL. 1
ER -